Irinotecan Hydrochloride Liposome

ApprovedSmall molecule

Irinotecan Hydrochloride Liposome is one of 189 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

188

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaActive, not recruiting

Ewing SarcomaActive, not recruiting

Biliary Tract CancerNot yet recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Neuroendocrine CarcinomaApproved

Active, not recruiting

Ewing SarcomaPhase 1

Active, not recruiting

Biliary Tract CancerPhase 3

Not yet recruiting

Colorectal CancerPhase 2

Active, not recruiting

Gastric CancerApproved

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Irinotecan Hydrochloride Liposome

Luye Pharma Group Ltd.

Approved

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Ketalar

AAultman Health Foundation

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Ewing Sarcoma

NCT06340204

Phase 2Recruiting

Colorectal Cancer

NCT06763029

N/ANot yet recruiting

Biliary Tract Carcinoma

NCT06463548

Q4 2027

Post-ApprovalNot yet recruiting

Gastric Cancer

NCT06499610

N/ARecruiting

Chemoradiotherapy

NCT06894797

Post-ApprovalNot yet recruiting

Neuroendocrine Carcinoma

NCT07014540

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 3·NCT06128837·686 enrolled

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Recruiting·TTang-Du Hospital·Phase 4·NCT06467786·24 enrolled

Colorectal Cancer1 trial

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06763029·36 enrolled

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Recruiting·FFudan University·Phase 2·NCT07183865·44 enrolled

Chemoradiotherapy1 trial

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT06894797·68 enrolled

Metastatic Biliary Tract Carcinoma1 trial

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting·BBa Yi·Phase 2·NCT06430827·20 enrolled

5 more indications

Ewing sarcoma1 trial

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Recruiting·PPeking University People's Hospital·Phase 1·NCT06340204·44 enrolled

Gastric Cancer1 trial

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT06499610·44 enrolled

Biliary Tract Carcinoma1 trial

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Not yet recruiting·YYunpeng Liu·N/A·NCT06463548·30 enrolled

Neuroendocrine Carcinoma1 trial

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not yet recruiting·—·Phase 4·NCT07014540·45 enrolled

Biliary Tract Cancer1 trial

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07582315·538 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Irinotecan Hydrochloride Liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Irinotecan Hydrochloride Liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Irinotecan Hydrochloride Liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Luye Pharma Group Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Luye Pharma Group Ltd.

Irinotecan Hydrochloride Liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Colorectal Cancer1 trial

Hypofractionated Radiotherapy1 trial

Chemoradiotherapy1 trial

Metastatic Biliary Tract Carcinoma1 trial

Ewing sarcoma1 trial

Gastric Cancer1 trial

Biliary Tract Carcinoma1 trial

Neuroendocrine Carcinoma1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News